What You Will Learn

Please join Carterra at our upcoming symposium in South San Francisco, CA. You will spend the day learning about high-throughput drug discovery and antibody therapeutics with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Antibody discovery in 90 days! Screening, identification & characterization
New methods in DELs, PROTACs and other formats
New technology and innovations during the pandemic
Data analysis routines & automation
Best practices in analyzing SPR data

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Agenda

8:45am – 9:00am	Arrive and Check-in
9:00am – 9:30am	Networking and Coffee/Tea
9:30am – 9:45am	Symposium Begins—Welcome
9:45am – 10:30am	Kate Hastie, PhD, Instructor, Ollmann Saphire Lab, La Jolla Institute for Immunology Keynote Address—From Alpha to Omicron: A global consortium study to identify broadly reactive SARS-CoV2 therapeutic antibodies
	Abstract: The Coronavirus Immunotherapeutic Consortium (CoVIC) was formed to develop prevention and therapeutic strategies against SARS-CoV-2 that could be mobilized in low- and middle-income countries. With now almost 400 unique antibodies, CoVIC has mapped the epitope landscape on the SARS-CoV-2 Spike protein using the Carterra LSA platform. This information, coupled with high throughput viral neutralization screens and in vivo protection studies, has revealed key communities of receptor-binding domain (RBD)-targeted antibodies that are resistant to major emerging variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.
10:30am – 11:00am	Derek Croote, PhD, Chief Technical Officer, IgGenix High-Affinity Monoclonal IgE Antibodies Underlie Tree Nut Co-allergy
	Abstract: Tree nut allergies are growing in prevalence and there is a need to understand the molecular bases of clinical phenotypes. IgGenix applied its novel discovery platform to isolate rare IgE antibodies responsible for allergic reactivity from human allergic subjects. These antibodies exhibit high affinity and cross-reactivity to well-characterized tree nut allergens in ways that recapitulate clinical co-allergy.
11:00am – 11:30am	Break and Networking
11:30am – 12:00pm	Dan Bedinger, PhD, Applications Science Team Lead, Carterra Best Practices for Designing and Analyzing Epitope Binning Experiments Using the Carterra LSA and Epitope Software
	Abstract: We will describe practical guidelines for designing, executing and analyzing epitope binning assays using Carterra’s LSA and industry-leading Epitope™ software. We will provide tips and tricks for leveraging the power of our software to groom a data set, remove unnecessary complexity, and apply community analysis while retaining sufficient nuance to most accurately describe the epitope landscape.
12:00pm – 1:00pm	Lunch
1:00pm – 1:30pm	Noah T. Ditto, Technical Product Manager, Carterra New Applications Using HT-SPR Technology
	Abstract: From kinetics to epitope characterization, HT-SPR has become an indispensable technology for the characterization of biotherapeutics. This presentation will focus on recently developed assays that expand the versatility of HT-SPR in the biotherapeutic space as well as move into new areas drug discovery. Topics include potency-based assays in addition to approaches focused on characterization of small molecule formats including targeted protein degraders (TPDs) and DNA encoded libraries (DELs).
1:30pm – 2:00pm	Tom Lopez, PhD, Antibody Discovery and Engineering, Surrozen Antibody Discovery and Engineering at Surrozen
	Abstract: Surrozen is a regenerative medicine company focused on Wnt signaling. The Wnt pathway is a master regulator of many biological processes such as injury repair and tissue homeostasis. Surrozen’s technology enables the generation of molecules with drug-like properties for tissue-targeted Wnt pathway modulation. High throughput SPR is central to enabling the design and generation of our novel class of molecules. This presentation will highlight how Surrozen utilizes the Carterra LSA to discover, characterize, and optimize our antibody-based platform.
2:00pm – 2:30pm	Break and Networking
2:30pm – 3:00pm	Denisa Foster, Protein Biochemist, Eli Lilly Rapid Epitope Characterization for the Discovery of LY-CoV1404
	Abstract: LY-CoV1404 (bebtelovimab) binds the RBD of SARS-CoV-2 in a highly conserved region and was identified to be a potent neutralizer for all of variants of concern. Epitope binning facilitated selection of an antibody that has a different epitope from many of the current clinical antibodies.
3:00pm – 3:30pm	Heather Schwoebel, Chief Business Officer, Alloy Therapeutics Lucy Liu, PhD, Senior Director and Head of Protein Analytics, Alloy Therapeutics Fully Integrated Antibody Discovery for the Biotechnology Ecosystem
	Abstract: Alloy Therapeutics is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and capabilities that are foundational for discovering and developing therapeutic biologics. Its fully integrated discovery service offering, DeepImmune™, deploys in vivo, in vitro, and in silico discovery and optimization technologies to find partners the best therapeutic antibody candidates. Alloy Chief Business Officer Heather Schwoebel and Head of Protein Analytics Lucy Liu will discuss how the Carterra LSA fits into this workflow and supports its efforts to enable the global scientific community to make better medicine together.
3:30pm – 4:00pm	Networking and 100th LSA Celebration – Sponsored by Alloy Therapeutics
4:00pm	Symposium Ends

What You Will Learn

Register Here

Agenda